Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

Late-stage pain pipeline refuses to swell
EP Vantage
Tue, 04/26/22 - 10:29 pm
Tags:
painkillers, Vertanical, Teva Pharmaceutical, Regeneron, Ampio Pharmaceuticals, Biogen, Eli Lilly, Vertex Pharmaceuticals, AstraZeneca, Acadia Pharmaceuticals
Regeneron CEO's pay drops 95%—but that shouldn't come as a shock
Fierce Pharma
Fri, 04/22/22 - 10:28 am
Tags:
Regeneron, Pharma CEOs, executive pay, Leonard Schleifer
Regeneron sees skin cancer potential beyond PD-1s with $250M Checkmate acquisition
Fierce Biotech
Tue, 04/19/22 - 11:10 am
Tags:
Regeneron, Checkmate Pharmaceuticals, M&A, skin cancer, vidutolimod
Regeneron's bid for COVID-19 drug's full approval hits snag as FDA extends review
Fierce Pharma
Thu, 04/14/22 - 10:56 am
Tags:
Regeneron, REGEN-COV, FDA, COVID-19, antibodies
Hunting for next big eye disease drug, Regeneron gets deeper into gene therapies with ViGeneron pact
Fierce Biotech
Wed, 04/6/22 - 12:18 pm
Tags:
Regeneron, gene therapy, ViGeneron, retinal disease
ACC 2022 – Astra’s cholesterol lowerer surprise comes just a little late
EP Vantage
Tue, 04/5/22 - 10:59 am
Tags:
AstraZeneca, Ionis Pharmaceuticals, AZD8233, cholesterol, ACC, Amgen, Sanofi, Novartis, Regeneron
FDA accepts Regeneron, Sanofi’s Dupixent for priority review
Pharmaceutical Business Review
Tue, 04/5/22 - 10:53 am
Tags:
Regeneron, Sanofi, Dupixent, FDA, eosinophilic esophagitis
Lilly, after making $1B bet, posts 'compelling' late-phase data on Dupixent rival
Fierce Biotech
Mon, 03/28/22 - 10:20 am
Tags:
Eli Lilly, lebrikizumab, Demira, Sanofi, Regeneron, Dupixent, atopic dermatitis
BioNTech and Regeneron expand their cancer partnership, pushing new Libtayo combo into NSCLC
Endpoints
Tue, 03/8/22 - 10:41 am
Tags:
BioNTech, Regeneron, lung cancer, vaccines, MRNA, Libtayo
Regeneron loses bid to scrap infringement lawsuit linked to COVID antibody cocktail
Fierce Pharma
Fri, 03/4/22 - 10:20 am
Tags:
Regeneron, Pfizer, BioNTech, patents, COVID-19, legal, antibody cocktail
Sanofi chases fourth Dupixent nod after late-stage eosinophilic esophagitis trial win
Fierce Pharma
Mon, 02/28/22 - 11:42 pm
Tags:
Sanofi, Regeneron, eosinophilic esophagitis, Dupixent, clinical trials
Kodiak's Eylea rival hits 'major disappointment' with failure in first of 6 phase 3 studies
Fierce Biotech
Wed, 02/23/22 - 09:28 pm
Tags:
Kodiak Sciences, KSI-301, Eylea, Bayer, Regeneron
Kiniksa inks licensing deal to take a Regeneron castoff into Asian markets
Endpoints
Wed, 02/23/22 - 10:31 am
Tags:
Kiniksa Pharmaceuticals, Regeneron, Arcalyst, Huadong Medicine, Asia, mavrilimumab
Sanofi's Dupixent falls short in phase 3 chronic spontaneous urticaria trial
Pharmaforum
Fri, 02/18/22 - 10:40 am
Tags:
Sanofi, Regeneron, clinical trials, Dupixent, chronic spontaneous urticaria
COVID-19 treatments earned 4 drugmakers $14B in 2021
Beckers Hospital Review
Tue, 02/8/22 - 11:50 pm
Tags:
Eli Lilly, Gilead Sciences, Merck, Regeneron, COVID-19, earnings
Roche grabs FDA okay for would-be blockbuster eye drug faricimab
Pharmaforum
Mon, 01/31/22 - 10:51 am
Tags:
Roche, faricimab, Eylea, Bayer, Regeneron, FDA
Roche looks to compete against a blockbuster with its newly approved vision drug
Stat
Sun, 01/30/22 - 11:53 am
Tags:
Roche, FDA, bispecific antibodies, Regeneron, Vabysmo, wet age-related macular degeneration, diabetic macular edema
Regeneron and Sanofi pull Libtayo app in cervical cancer, citing post-market study disagreement with FDA
Endpoints
Sun, 01/30/22 - 11:42 am
Tags:
Sanofi, Regeneron, Libtayo, cervical cancer, post-marketing studies
FDA bans use of Lilly, Regeneron COVID drugs due to Omicron
Pharmaforum
Tue, 01/25/22 - 10:44 am
Tags:
COVID-19, Eli Lilly, Regeneron, antibodies, Omicron COVID-19 variant
Regeneron announces FDA acceptance for sBLA review of Libtayo with chemotherapy for NSCLC
Pharmaceutical Business Review
Thu, 01/20/22 - 11:00 am
Tags:
Regeneron, FDA, Libtayo, non-small cell lung cancer

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.